The deletion of the TP53 gene is more frequent in solid tumors and occurs in 20% of patients in the blast phase of CML and is interpreted as a genetic marker of poor prognosis because monosomy may be part of the mechanism of loss of heterozygosity of this suppressor gene tumor [26,27]. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.